C-reactive protein and cardiovascular disease: A review of risk prediction and interventions

Clinica Chimica Acta

Volumn 317, Issue 1-2, 2002, Pages 1-15

  De Ferranti, Sarah ^a   Rifai, Nader ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

C reactive protein; Cardiovascular disease; Inflammation; Review

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

AGE; ANGINA PECTORIS; ARTERIOSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; NONHUMAN; OBESITY; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; RELIABILITY; REVIEW; RISK FACTOR; SCREENING; SMOKING; TREATMENT OUTCOME; TREATMENT PLANNING;

AGE FACTORS; ARTERIOSCLEROSIS; ASPIRIN; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; OBESITY; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SMOKING; TREATMENT OUTCOME;

ANGINA;

EID: 0036157628     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(01)00797-5     Document Type: Review

References (90)

1. Prevalence of nonfatal coronary heart disease among American adults
2. Range of serum cholesterol values in the population developing coronary artery disease
3. Distribution of lipids in 8500 men with coronary artery disease
4. A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results
5. Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference intervals and epidemiological applications
6. Acute-phase proteins and other systemic responses to inflammation
7. Complement activation by C-reactive protein complexes
8. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease
9. Increased levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability
10. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses
11. Inflammation in cardiovascular disease: Cart, horse or both?
12. C-reactive protein-mediated low density lipoprotein uptake by macrophages: Implications for atherosclerosis
13. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenona?
14. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease
15. Direct proinflammatory effect of C-reactive protein on human endothelial cells
16. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
17. Evaluation of four automated high-sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications
18. Evaluation of nine automated high sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications. Part 2
19. Absence of Diurnal variation of C-reactive protein levels in healthy human subjects
20. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults
21. Long-term effects of pravastatin on plasma concentration of C-reactive protein
22. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction
23. Control of the acute phase response: Serum C-reactive protein kinetics after acute myocardial infarction
24. Intravenous streptokinase treatment and serum C-reactive protein in patients with acute myocardial infarction
25. C-reactive protein on admission as a predictor of in-hospital death in the elderly with acute myocardial infarction
26. Enhanced inflammatory response in patients with preinfarction unstable angina
27. Independent prognostic value of increased C-reactive protein in unstable angina
28. Equivalent early sensitivities of myoglobin, creatine kinase MB mass, creatine kinase isoform ratios, and cardiac troponins I and T for acute myocardial infarction
29. Comparison of the prognostic value of C-reactive protein and troponin I in patients with unstable angina pectoris
30. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina
31. Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction
32. C-reactive protein is a potent predictor of mortality independently or in combination with TnT in acute coronary syndromes: A TIMI 11 sub study
33. Incremental prognostic value of serum levels of TnT and C-reactive protein on admission in patients with unstable angina pectoris
34. Predictive value of C-reactive protein and TnT in patients with unstable angina: A comparative analysis
35. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease
36. High-sensitivity C-reactive protein is a potent predictor of long-term mortality in 3225 patients with acute coronary syndromes; results from OPUS-TIMI 16
37. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
38. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina
39. Production of C-reactive protein and risk of coronary events in stable and unstable angina
40. Elevation of C-reactive protein in "Active" coronary artery disease
41. C reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study
42. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study
43. Inflammation, aspirin, and risks of cardiovascular disease in apparently healthy men
44. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg cohort study, 1984 to 1992
45. Fibrinogen, C-reactive protein, albumin or white cell count: Meta-analysis of prospective studies of coronary heart disease
46. Infections, inflammation, and the risk of coronary heart disease
47. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
48. C-reactive protein: Relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men
49. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses
50. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: Results from the Cardiovascular Health Study and the Rural Health Promotion Project
51. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
52. Lovastatin 20-40 mg/day lowers high sensitivity C-reactive protein levels in AFCAPS/TexCAPS
53. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
54. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
55. Hormone replacement therapy, inflammation, and hemostatsis in elderly women
56. Hormone replacement therapy and increased plasma concentration of C-reactive protein
57. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, Placebo-controlled study
58. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial
59. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) study
60. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
61. Immunoradiometric assay of circulating C-reactive protein: Age-related values in the adult general population
62. Interrelations of blood pressure, interleukin-6 (IL-6), and intercellular adhesion molecul-1 (sICAM-1) in apparently healthy men
63. Retinal vein occlusion: C-reactive protein and arterial hypertension
64. Raised C-reactive protein levels from smokers
65. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects
66. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue?
67. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women
68. Elevated C-reative protein levels in overweight and obese adults
69. C-reactive protein concentration in children: Relationship to adiposity and other cardiovascular risk factors
70. Human subcutaneous adipose tissue releases IL-6 but not TNF-alpha in vivo
71. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease
72. Atherosclerosis and inflammation: Patterns of cytokine regulation in patients with peripheral artery disease
73. Novel risk factors for systemic atherosclerosis: A comparison of C reactive protein, fibrinogen, homocysteine, lipoprotein(a) and standard cholesterol screening as predictors of peripheral arterial disease
74. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain
75. High-sensitivity C-reactive protein: A novel and promising marker of coronary heart disease
76. C-reactive protein and atherosclerosis: From theory to therapy
77. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin
78. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
79. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
80. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and abroad range on initial cholesterol levels
81. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCaps
82. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
83. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP elvatuation (PRINCE): A randomized trial and cohort study
84. Effect of HMG-CoA reductase inhibitors therapy on high sensitivity C-reactive protein levels
85. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia
86. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques: Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits
87. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
88. An HMG-CoA reductase inhibitor (Cerivastatin) suppresses accumulation of macrophages expressing matrix metalloproteinases and tissue factoring atheroma of WHHL rabbits
89. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro
90. C-reactive protein in offspring is associated with the occurrence of myocardial infarction in first-degree relatives